Bolla Daniele, Weissleder Saskia Vanessa, Radan Anda-Petronela, Gasparri Maria Luisa, Raio Luigi, Müller Martin, Surbek Daniel
Department of Obstetrics and Gynaecology, Inselspital, Bern University Hospital, University of Bern, Effingerstrasse 102, CH-3010, Bern, Switzerland.
Departments of Obstetrics, Gynaecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA.
BMC Pregnancy Childbirth. 2018 May 10;18(1):149. doi: 10.1186/s12884-018-1788-z.
Misoprostol vaginal insert for induction of labor has been recently reported to be superior to dinoprostone vaginal insert in a phase III trial, but has never been compared to vaginal misoprostol in another galenic form. The aim of this study was to compare misoprostol vaginal insert (MVI) with misoprostol vaginal tablets (MVT) for induction of labor in term pregnancies.
In this retrospective cohort study we compared 200 consecutive women induced with 200-μg misoprostol 24-h vaginal insert (Misodel®) with a historical control of 200 women induced with Misoprostol 25-μg vaginal tablets (Cytotec®) every 4-6 h. Main outcomes variables included induction-to-delivery interval, vaginal delivery within 24-h, incidence of tachysystole, mode of delivery, and neonatal outcome. A subanalysis in the MVI group was performed in order to identify predictive factors for tachysistole and vaginal delivery within 24 h.
The time from induction to vaginal delivery was 1048 ± 814 min in the MVI group and 1510 ± 1043 min in the MVT group (p < 0.001). Vaginal delivery within 24-h occurred in 127 (63.5%) patients of the MVI group and in 110 (55%) patients of the MVT group (p < 0.001). Tachysystole was more common in the MVI group (36% vs. 18%; p < 0.001). However, no significant predictors of uterine tachysystole in MVI group have been identified in crude and fully adjusted logistic regression models. Bishop score was the only predictor for vaginal delivery within 24 h (p < 0.001) in MVI group. Caesarean delivery rate (27% vs. 20%) and vaginal-operative deliveries (15.5% vs. 15.5%) did not differ significantly between the two groups. Neonatal outcomes were similar in both groups.
MVI achieves a more vaginal delivery rate within 24 h and Tachysystole events compared to MVT. However, no differences in caesarean section, operative vaginal delivery, and neonatal outcomes are reported. No predictors of tachysistole after MVI administration have been identified. Bishop score and parity are the only predictors of vaginal delivery within 24 h after MVI administration.
近期一项Ⅲ期试验报告称,用于引产的米索前列醇阴道栓剂优于地诺前列酮阴道栓剂,但从未与其他剂型的阴道米索前列醇进行过比较。本研究旨在比较米索前列醇阴道栓剂(MVI)与米索前列醇阴道片(MVT)用于足月妊娠引产的效果。
在这项回顾性队列研究中,我们将连续200例接受200μg米索前列醇24小时阴道栓剂(Misodel®)引产的妇女与200例接受每4 - 6小时25μg米索前列醇阴道片(Cytotec®)引产的历史对照患者进行了比较。主要结局变量包括引产至分娩间隔、24小时内阴道分娩、宫缩过速发生率、分娩方式和新生儿结局。对MVI组进行了亚分析,以确定宫缩过速和24小时内阴道分娩的预测因素。
MVI组引产至阴道分娩的时间为1048±814分钟,MVT组为1510±1043分钟(p<0.001)。MVI组127例(63.5%)患者在24小时内阴道分娩,MVT组110例(55%)患者在24小时内阴道分娩(p<0.001)。宫缩过速在MVI组更常见(36%对18%;p<0.001)。然而,在未调整和完全调整的逻辑回归模型中,均未在MVI组中确定子宫宫缩过速的显著预测因素。Bishop评分是MVI组24小时内阴道分娩的唯一预测因素(p<0.001)。两组间剖宫产率(27%对20%)和阴道助产率(15.5%对15.5%)无显著差异。两组新生儿结局相似。
与MVT相比,MVI在24小时内实现了更高的阴道分娩率和更多的宫缩过速事件。然而,剖宫产、阴道助产和新生儿结局方面未报告差异。未确定MVI给药后宫缩过速的预测因素。Bishop评分和产次是MVI给药后24小时内阴道分娩的唯一预测因素。